Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 42Parkinson Disease 4, Autosomal Dominant Lewy Body 29Carcinoma, Renal Cell 26Endometrial Neoplasms 13Melanoma 10Neoplasms 8Uterine Cervical Neoplasms 7Cholangiocarcinoma 7Biliary Tract Neoplasms 7Liver Neoplasms 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Neuroendocrine Tumors 5Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Carcinoma, Anaplastic 3Recurrence 3Kidney Neoplasms 3Esophageal Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Adenoid Cystic 3Breast Neoplasms 3Brain Neoplasms 3Adenocarcinoma 3Vulvar Neoplasms 2

Interventions

pembrolizumab 6Cetuximab 5olaparib 3atezolizumab 3Injections 3fludarabine 2Trastuzumab 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2zimberelimab 1zansecimab 1tocilizumab 1taxane 1spartalizumab 1somatostatin receptor 2 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1lenvatinib 1ipatasertib 1inavolisib 1fludarabine phosphate 1entrectinib 1encorafenib 1durvalumab 1dapagliflozin 1cemiplimab 1brigimadlin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × lenvatinib × 1 year × Clear all
NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Tongji Hospital

Phase 2 Not yet recruiting
60 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡